Genetic Technologies Limited Announces Further Collaborative Research with The University of Melbourne

Genetic Technologies (ASX:GTG) (Nasdaq:GENE) a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today the execution of a research and services agreement with The University of Melbourne for the further development and enhancement of the BREVAGenplus breast cancer risk assessment test.

As quoted in the press release:

Whilst the terms of the agreement are confidential, the work will be a continuation of the substantial research program led by Prof John Hopper and his research team within the Centre for Epidemiology and Biostatistics at The University of Melbourne. The research is designed to broaden the applicability of the BREVAGenplus breast cancer risk assessment test enabling its use by women with an extended family history of disease and will also increase the range of risk factors analyzed. The collaboration is designed to further improve physicians’ ability to manage breast cancer by improving the accuracy of risk prediction.

Click here to read the full press release.